[1]Xia XY,Wang XM.Progression of transforming growth factor-β1 in tumor[J].Modern Oncology,2014,22(03):710-713.[夏现印,王秀梅.化生长因子-β1 在肿瘤中的研究进展[J].现代肿瘤医学,2014,22(03):710-713.]
[2]Zhu ZL,Yan Z.Research progress on therapeutic strategies targeting the glutathione antioxidant system in cancer cells to reverse drug resistance[J].Chin J Clin Oncol,2015,42(23):1143-1147.[朱仲玲,阎昭.靶向谷胱甘肽抗氧化系统逆转肿瘤耐药的研究进展[J].中国肿瘤临床,2015,42(23):1143-1147.]
[3]Song JS,Lim DH,Chung ES,et al.Mutation analysis of the TGFBI gene in consecutive korean patients with corneal dystrophies[J].Ann Lab Med,2015,35(3):336-340.
[4]Gao X,Ye Z,Wu KX,et al.Effects of α-enolase silencing on drug resistance in drug resistant cell line K562/A02[J].Chin Pharmacological Bulletin,2014,30(11):1521-1525,1526.[高雪,叶舟,吴克雄,等.干扰α烯醇化酶对耐药细胞株K562/A02耐药性的影响[J].中国药理学通报,2014,30(11):1521-1525,1526.]
[5]Burrell RA,Swanton C.Tumour heterogeneity and the evolution of polyclonal drug resistance[J].Mol Oncol,2014,8(6):1095-1111.
[6]Guo YK,Shi M,Qin YL,et al.Research progess in molecular mechanism of resveratrol-mediated reversal of tumor drug resistance[J].Basic & Clin Med,2016,36(3):401-405.[郭玉楷,史敏,秦永亮,等.白藜芦醇逆转肿瘤耐药的分子机制研究进展[J].基础医学与临床,2016,36(3):401-405.]
[7]Chen P,Liu L.The research progress of the relationship between miR-21 through regulate its target gene PTEN and tumor resistance[J].Modern Oncology,2015,23(13):1917-1920.[陈彭,刘利.miR-21作用于PTEN与肿瘤耐药关系的研究进展[J].现代肿瘤医学,2015,23(13):1917-1920.]
[8]Lin GY,Xu K.Advances in tumor chemo-resistance regulated by microRNA[J].Chin J Lung Cancer,2014,17(10):741-749.[林高阳,徐克.MicroRNA调控肿瘤耐药的研究进展[J].中国肺癌杂志,2014,17(10):741-749.]
[9]Irigoyen M,Pajares MJ,Agorreta J,et al.TGFBI expression is associated with a better response to chemotherapy in NSCLC[J].Mol Cancer,2010,28(9):130.
[10]Cao YM,Zhang HM,Gao SH,et al.Transforming growth factor-β induced gene inhibits cell proliferation of malignant mesothelioma in vitro[J].Cancer Res Prey Treat,2013,40(12):1123-1127.[曹艳梅,张鹤美,高四海,等.转化生长因子β诱导的基因抑制恶性间皮瘤细胞增殖的体外研究[J].肿瘤防治研究,2013,40(12):1123-1127.]
[11]Wang N,Zhang H,Yao Q,et al.TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer[J].J Exp Clin Cancer Res,2012,16(31):6-7.
[12]Zhang HM,He JJ,Gao SH,et al.TGFBI Inhibits proliferation of breast cancer cell in vitro and in vivo[J].Cancer Res Prey Treat,2014,41(7):693-697.[张鹤美,贺金奖,高四海,等.外源性TGFBI抑制乳腺癌细胞生长的体内外实验[J].肿瘤防治研究,2014,41(7):693-697.]
[13]Xu JH,Hu SL,Shen GD,et al.Tumor suppressor genes and their underlying interactions in paclitaxel resistance in cancer therapy[J].Cancer Cell Int,2016,20(16):13.
[14]Zhang ZQ,Wei YX,Zhao Q,et al.Reversal effect vatalanib on BCRP-mediated multidrug resistance[J].Chin Pharmacological Bulletin,2014,36(6):774-781,782.[张志强,魏寅祥,赵青,等.瓦他拉尼对乳腺癌耐药蛋白介导的肿瘤多药耐药的逆转研究[J].中国药理学通报,2014,36(6):774-781,782.]
[15]Tumbarello DA,Temple J,Brenton JD.β3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells[J].Mol Cancer,2012,28(11):36.
[16]Wang JJ,Zhang WM,Chen B,et al.The role of epithelial-mesenchymal transition and insulin-like growth factorⅠreceptor in acquired resistance to epidermal growth factor-tyrosine kinase inhibitors in non-small cell lung cancer[J].Tumor,2013,33(2):103-110.[王津京,张为民,陈蓓,等.上皮-间质转化和胰岛素样生长因子Ⅰ型受体在非小细胞肺癌EGFR-TKIs获得性耐药中的作用[J].肿瘤,2013,33(2):103-110.]